NEW YORK, June 14, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Regeneron Pharmaceuticals, Inc.: PharmaVitae Report
http://www.reportlinker.com/p0885025/Regeneron-Pharmaceuticals-Inc-PharmaVitae-Report.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology
ABOUT THIS REPORT•PharmaVitae Explorer database
•Chapter structure - Sales and product analysis
- Financial analysis
•Data sourcing - Analyst consensus
EXECUTIVE SUMMARY•Company introduction - Recent developments
- Corporate relationships
- Bayer
- Astellas
- Novartis
- Roche/Genentech
•Strategic overview
•SWOT analysis - Strengths
- Weaknesses
- Opportunities
- Threats
SALES AND PRODUCT ANALYSIS•Sales overview
•Product analysis - Product sales
•Eylea (intraocular affablest; VEGF Trap-Eye) - Disease background
- CATT trial
- Retinal vein occlusion
- Diabetic macular edema
- Wet AMD clinical trials
- Opinions of Eylea
- Use in retinal vein occlusion and diabetic macular edema
- BRVO trial
- DME trial
- Current use of anti-VEGF agents in RVO and DME
- Key forecasting assumptions
- CRVO
- BRVO
- DME
•Zaltrap (intravenous aflibercept; VEGF-Trap) - Colorectal cancer clinical trials
- Several factors may impact Zaltrap's uptake in the second-line setting
- Sanofi's presence in the colorectal cancer market will aid commercialization of Zaltrap
- Key forecasting assumptions
•Arcalyst (rilonacept) - Arcalyst CAPS sales to remain flat through forecast period
- Gout background
- Gout clinical trials
- Approval of Arcalyst for the prevention of gout flares appears unlikely following negative FDA panel vote
•Sarilumab (REGN88; IL-6R antibody)
•REGN727 (
SAR236553; PCSK9 antibody) - Regeneron and Sanofi have not disclosed plans for REGN727 Phase III development
•Earlier-stage products - REGN475 (
SAR164877; NGF antibody)
- REGN668 (
SAR231893; IL-4R antibody)
- REGN421 (
SAR153192; Dll4 antibody)
- REGN910 (
SAR307746; Ang2 antibody)
- REGN846
- REGN728
- REGN1033
- REGN1154
FINANCIAL ANALYSIS•Financial performance overview - Operating costs and profit analysis, 2005–11
- Operating costs and profit analysis, 2011–17
APPENDIX•References - Datamonitor reports
•Exchange rates
TABLES•Table: Regeneron R&D pipeline
•Table: Regeneron catalyst timeline
•Table: Regeneron product portfolio overview ($m), 2011–17
•Table: Regeneron/Bayer-sponsored Eylea clinical trials, ongoing
•Table: Overview of pivotal Phase III data for Eylea in wet AMD
•Table: Overview of pivotal Phase III data for Eylea and Lucentis in macular edema secondary to CRVO
•Table: Eylea US wet AMD forecast model, 2012–17
•Table: Eylea US RVO forecast model, 2012–17
•Table: Eylea US DME forecast model, 2012–17
•Table: Worldwide Eylea sales, 2012–17
•Table: Zaltrap colorectal cancer clinical trials
•Table: Summary of results from the Phase III VELOUR trial
•Table: Zaltrap sales forecast, seven major markets ($m), 2012–17
•Table: Arcalyst gout Phase III trials
•Table: Summary of results from the Phase III PRE-SURGE trials
•Table: Sarilumab trials
•Table: Summary of results from the Phase IIb portion of the MOBILITY trial
•Table: REGN727 trials
•Table: Regeneron operating revenue/cost analysis ($m), 2005–11
•Table: Regeneron operating revenue/cost analysis ($m), 2011–17
•Table: Exchange rates, 2011
FIGURES•Figure: PharmaVitae Explorer
•Figure: Regeneron prescription pharmaceutical performance, sales ($m) and growth rate (%), 2011–17
•Figure: Regeneron sales ($m), 2011–17
•Figure: In October 2011 (immediately prior to the approval of Eylea), what percentage of your treated wet AMD patients were receiving the following treatments?
•Figure: Following the 2-year results of the CATT trial, how do you view Avastin versus Lucentis in terms of efficacy/safety?
•Figure: Based on your knowledge of the three anti-VEGF agents, please rate them on a scale from 1 to 5 on the following attributes, where 1=poor and 5=excellent.
•Figure: Of the patients to whom you have administered Eylea, what percentage falls into each of the following categories? (Weighted average)
•Figure: So far this year, what percentage of your newly diagnosed patients received the following agents as their first-line therapy? Three years from now, what percentage of your newly diagnosed patients do you expect will receive the following agents as their first-line therapy?
•Figure: Of your patients failing their first-line therapy, what percentage do you expect will receive Avastin, Lucentis, or Eylea as a second-line therapy?
•Figure: Of your CRVO/BRVO/DME patients, what percentages are currently treated with the following?
•Figure: Regeneron operating/cost performance ($m), 2005–17
Companies mentioned
Bunzl plc, BWT AG, Hutchison 3G UK Limited, Ipsen S.A., Merck KGaA, QLT Inc., VINCI
To order this report:
: Regeneron Pharmaceuticals, Inc.: PharmaVitae Report
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article